• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

    104.01 +0.59 (+0.57%)
    Streaming Delayed Price Updated: 12:54 PM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Spyre Therapeutics, Inc. - Common Stock

    News headline image
    Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Participate in Upcoming June Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Participate in Upcoming March Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Participate in Upcoming November Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.